RETATRUT

Recovery, Metabolic & Body Composition Support

RETATRUT is a next-generation injectable peptide developed to support recovery, metabolic function, and body composition during periods of increased physical or metabolic demand.

When RETATRUT is selected:

• Following injury or intensive training

• In cases of overweight or obesity

• During structured fat-reduction phases

• In insulin resistance and carbohydrate metabolism disorders

• For appetite regulation and eating behavior management

• In metabolic syndrome or reduced insulin sensitivity

Key properties:

• Supports recovery of muscle and connective tissues

• Participates in the regulation of metabolic processes

• Delays gastric emptying

• Reduces appetite and caloric intake

• Promotes recovery following physical exertion

Clinical effects:

• Reduction of body weight primarily through fat mass loss

• Improved glycemic control

• Increased insulin sensitivity

• Decreased appetite and food cravings

• Positive influence on overall energy balance

In clinical studies, participants receiving retatrutide at 12 mg weekly achieved an average body weight reduction of approximately 24% over 48 weeks. In adults with type 2 diabetes, retatrutide (up to 12 mg weekly) resulted in approximately 17% body weight reduction over 36 weeks.

Pharmaceutical quality:

• Synthetic peptide with a precisely defined molecular structure

• High degree of purification

• Stable pharmaceutical formulation

• Manufactured in compliance with GMP standards

Dosage form:

Lyophilized white or off-white powder for preparation of a solution for injection.

After reconstitution, a clear, colorless solution free of visible particles is obtained.

Packaging:

• 1 vial × 10 mg

• 2 vials × 10 mg

Storage conditions:

After reconstitution, store refrigerated at 2–8°C (36–46°F) and use within 38 days.

Do not freeze.

Administration:

Reconstitution: Add 1.0 mL of bacteriostatic water → final concentration 1.0 mg/mL.

Weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).

Measurement reference: At 10 mg/mL, 1 unit (0.01 mL) = 0.1 mg (100 mcg) using a U-100 insulin syringe.

Dosage & Titration:

Recommended gradual weekly dose-escalation approach:

Initiation: 2 mg once weekly during the first 4 weeks to establish baseline tolerance.

Escalation: Increase to 4 mg weekly (weeks 5–8), then to 8 mg weekly (weeks 9–12).

Maintenance: 12 mg weekly (from week 13 onward) for maximal efficacy; 8 mg weekly may serve as an alternative maintenance dose.

Frequency: Once weekly (subcutaneous injection).

Cycle duration: Minimum 12 weeks. Clinical studies have been conducted for up to 48 weeks, demonstrating sustained weight reduction.

Timing: Administer on the same day each week at any time; rotate injection sites to minimize local irritation.

Laboratory Verification:

Certificate of Analysis (CoA):

BioRegen:

Manufacturer:

American Pharmaceutical, Inc.

Ohio, USA